BioScrip Inc. (NASDAQ:BIOS) shares fell 1% during trading on Tuesday . The stock traded as low as $2.82 and last traded at $2.89, with a volume of 819,491 shares traded. The stock had previously closed at $2.92.

Separately, Zacks Investment Research raised BioScrip from a “sell” rating to a “hold” rating in a research note on Friday, June 17th.

The stock’s market capitalization is $326.84 million. The stock has a 50 day moving average of $2.70 and a 200 day moving average of $2.55.

BioScrip (NASDAQ:BIOS) last announced its earnings results on Monday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.05. The firm earned $232.50 million during the quarter, compared to analysts’ expectations of $229.58 million. BioScrip had a negative return on equity of 609.04% and a negative net margin of 5.63%. BioScrip’s revenue for the quarter was down 11.4% compared to the same quarter last year. On average, equities research analysts expect that BioScrip Inc. will post ($0.27) EPS for the current year.

In other news, Director Coliseum Capital Management, L bought 4,200,000 shares of the company’s stock in a transaction on Wednesday, June 22nd. The shares were acquired at an average cost of $2.00 per share, with a total value of $8,400,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.60% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Metropolitan Life Insurance Co. NY purchased a new position in shares of BioScrip during the second quarter valued at about $152,000. Oxford Asset Management bought a new position in BioScrip during the second quarter valued at approximately $176,000. PNC Financial Services Group Inc. increased its position in BioScrip by 368.4% in the second quarter. PNC Financial Services Group Inc. now owns 74,362 shares of the company’s stock valued at $190,000 after buying an additional 58,486 shares during the period. M&T Bank Corp bought a new position in BioScrip during the second quarter valued at approximately $204,000. Finally, Alliancebernstein L.P. increased its position in BioScrip by 15.2% in the second quarter. Alliancebernstein L.P. now owns 94,100 shares of the company’s stock valued at $240,000 after buying an additional 12,400 shares during the period. 85.91% of the stock is currently owned by institutional investors and hedge funds.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

5 Day Chart for NASDAQ:BIOS

Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.